• Inspire Medical Systems recently appointed Matt Osberg as Executive Vice President and Chief Financial Officer, while also issuing updated revenue guidance for the fourth quarter of 2025, full-year 2025, and full-year 2026.
• These developments coincided with new uncertainty around Medicare reimbursement after two regional contractors removed a key billing code for the company’s hypoglossal nerve stimulation therapy, raising questions about how payment policies could interact with Inspire’s growth plans.
• We’ll now examine how the Medicare billing code uncertainty, alongside Inspire’s revenue outlook, shapes the company’s broader investment narrative.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

What Is Inspire Medical Systems' Investment Narrative?

To own Inspire Medical Systems today, you need to be comfortable with a focused sleep‑apnea story that is increasingly tied to reimbursement decisions. The investment case still centers on growing adoption of hypoglossal nerve stimulation and translating that into higher revenue and improving profitability, as reflected in the company’s guidance for 2025 and 2026. The recent Medicare billing code change, which triggered a sharp share price drop, now sits at the heart of the short‑term catalyst and risk discussion: any clarification or reversal could influence how quickly new centers ramp and how confident hospitals feel about procedures. At the same time, the appointment of experienced CFO Matt Osberg adds financial leadership at a moment when investors are scrutinizing margins, cash flow, and capital allocation more closely than before.

However, the evolving Medicare billing stance could challenge parts of Inspire’s current growth playbook, which investors should understand. Inspire Medical Systems' share price has been on the slide but might be up to 14% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Nine Simply Wall St Community fair value estimates range from about US$69.63 to US$270.86, showing how far apart private investors are. Set that against the newly elevated reimbursement uncertainty and you can see why it makes sense to compare several viewpoints before deciding how Inspire’s risk and reward profile fits your own expectations.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth over 3x more than the current price!

Build Your Own Inspire Medical Systems Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.